VPS52

Summary

VPS52 (VPS52 subunit of GARP complex, HGNC:10518) is a protein-coding gene on chromosome 6p21.32, encoding Vacuolar protein sorting-associated protein 52 homolog (Q8N1B4). Acts as a component of the GARP complex that is involved in retrograde transport from early and late endosomes to the trans-Golgi network (TGN). It is a selective cancer dependency (DepMap: 30.3% of cell lines).

This gene encodes a protein that is similar to the yeast suppressor of actin mutations 2 gene. The yeast protein forms a subunit of the tetrameric Golgi-associated retrograde protein complex that is involved in vesicle trafficking from from both early and late endosomes, back to the trans-Golgi network. This gene is located on chromosome 6 in a head-to-head orientation with the gene encoding ribosomal protein S18. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 6293 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder with or without congenital anomalies (Moderate, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 99 total
• Cancer dependency (DepMap): dependent in 30.3% of screened cell lines
• MANE Select transcript: NM_022553

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10518
Approved symbol	VPS52
Name	VPS52 subunit of GARP complex
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Aliases	ARE1
Ensembl gene	ENSG00000223501
Ensembl biotype	protein_coding
OMIM	603443
Entrez	6293

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 14 protein_coding, 6 protein_coding_CDS_not_defined, 3 retained_intron

ENST00000445902, ENST00000461743, ENST00000463486, ENST00000464425, ENST00000471309, ENST00000478934, ENST00000482399, ENST00000493379, ENST00000493674, ENST00000495755, ENST00000495981, ENST00000865493, ENST00000865494, ENST00000865495, ENST00000865496, ENST00000865497, ENST00000865498, ENST00000865499, ENST00000920311, ENST00000954722, ENST00000954723, ENST00000954724, ENST00000954725

RefSeq mRNA: 4 — MANE Select: NM_022553 NM_001289174, NM_001289175, NM_001289176, NM_022553

CCDS: CCDS4770

Canonical transcript exons

ENST00000383210 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1921 / max 87.0869, expressed in 1811 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73111	12.0368	1782
73110	5.5958	1705
73112	0.4149	205
73109	0.1445	64

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	97.02	gold quality
right uterine tube	UBERON:0001302	97.00	gold quality
pituitary gland	UBERON:0000007	96.78	gold quality
metanephros cortex	UBERON:0010533	96.67	gold quality
right adrenal gland cortex	UBERON:0035827	96.60	gold quality
left lobe of thyroid gland	UBERON:0001120	96.59	gold quality
right adrenal gland	UBERON:0001233	96.53	gold quality
thyroid gland	UBERON:0002046	96.46	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.44	gold quality
spleen	UBERON:0002106	96.38	gold quality
adenohypophysis	UBERON:0002196	96.37	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.19	gold quality
cerebellar hemisphere	UBERON:0002245	96.09	gold quality
cerebellar cortex	UBERON:0002129	96.08	gold quality
cerebellum	UBERON:0002037	96.05	gold quality
left adrenal gland cortex	UBERON:0035825	95.98	gold quality
left adrenal gland	UBERON:0001234	95.97	gold quality
right ovary	UBERON:0002118	95.97	gold quality
fundus of stomach	UBERON:0001160	95.94	gold quality
skin of abdomen	UBERON:0001416	95.92	gold quality
body of pancreas	UBERON:0001150	95.90	gold quality
left ovary	UBERON:0002119	95.86	gold quality
tibial nerve	UBERON:0001323	95.85	gold quality
zone of skin	UBERON:0000014	95.83	gold quality
skin of leg	UBERON:0001511	95.82	gold quality
body of stomach	UBERON:0001161	95.73	gold quality
lower esophagus mucosa	UBERON:0035834	95.71	gold quality
apex of heart	UBERON:0002098	95.66	gold quality
minor salivary gland	UBERON:0001830	95.62	gold quality
small intestine	UBERON:0002108	95.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.83

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, NFE2L2

miRNA regulators (miRDB)

28 targeting VPS52, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-3147	99.52	66.34	388
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-548V	99.29	69.47	1157
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-6768-3P	99.14	67.38	1319
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4494	97.86	64.93	850
HSA-MIR-6783-5P	97.67	67.21	1528
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-342-5P	97.25	64.10	817
HSA-MIR-3972	97.19	66.46	808
HSA-MIR-1202	97.19	66.43	827
HSA-MIR-4513	95.04	67.06	727
HSA-MIR-6855-3P	95.04	66.57	725
HSA-MIR-6765-5P	94.51	62.65	164

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 30.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• Golgi associated retrograde protein complex, consisting of the Vps52, Vps53, and Vps54 proteins, shows significant conservation between various species but diversification and specialization result in important differences in human cells. (PMID:15878329)
• Missorting of cathepsin D in GARP-depleted cells results from accumulation of recycling MPRs in a population of light, small vesicles downstream of endosomes. (PMID:18367545)
• Golgi-associated retrograde protein orchestrates retrograde transport from endosomes to the trans-Golgi network by promoting vesicle tethering and assembly of SNARE complexes in consecutive, independent steps.[Golgi associated retrograde protein] (PMID:19620288)
• our data indicate that cisplatin resistance in HOCCs is partially attributable to their high expression of p62, which plays an important role in preventing ROS stress-induced apoptosis by regulating the Keap1-Nrf2-ARE signaling pathway. (PMID:25269472)
• These data demonstrate that the beneficial properties of SFN extend beyond activation of the KEAP1-Nrf2-ARE system and warrant further interrogation given the current use of this agent in multiple clinical trials (PMID:27889639)
• Loss of heterozygosity and stop-gain mutation of VPS52 were found in gastric cancer. (PMID:28791438)
• The Sac2 operates upstream of granule docking, since loss of Sac2 prevented granule tethering to the plasma membrane and resulted in both reduced granule density and number of exocytic events. (PMID:31533953)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	vps52	ENSDARG00000099258
mus_musculus	Vps52	ENSMUSG00000024319
rattus_norvegicus	Vps52	ENSRNOG00000000470
drosophila_melanogaster	Vps52	FBGN0031710
caenorhabditis_elegans		WBGENE00007059

Protein

Protein identifiers

Vacuolar protein sorting-associated protein 52 homolog — Q8N1B4 (reviewed: Q8N1B4)

Alternative names: SAC2 suppressor of actin mutations 2-like protein

All UniProt accessions (3): Q8N1B4, E9PI03, Q4VXZ2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a component of the GARP complex that is involved in retrograde transport from early and late endosomes to the trans-Golgi network (TGN). The GARP complex is required for the maintenance of the cycling of mannose 6-phosphate receptors between the TGN and endosomes, this cycling is necessary for proper lysosomal sorting of acid hydrolases such as CTSD. Acts as a component of the EARP complex that is involved in endocytic recycling. The EARP complex associates with Rab4-positive endosomes and promotes recycling of internalized transferrin receptor (TFRC) to the plasma membrane.

Subunit / interactions. Component of the Golgi-associated retrograde protein (GARP) complex, also called VFT (VPS fifty-three) complex, composed of VPS51, VPS52, VPS53 and VPS54. Component of the endosome-associated retrograde protein (EARP) complex, composed of VPS51, VPS52, VPS53 and VPS50/Syndetin. EIPR1 interacts with both EARP and GARP complexes and mediates the recruitment of the GARP complex to the trans-Golgi network. Interacts with RAB6A and STX10. Interacts with BLTP3B.

Subcellular location. Golgi apparatus. trans-Golgi network membrane. Endosome membrane. Recycling endosome.

Similarity. Belongs to the VPS52 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N1B4-1	1	yes
Q8N1B4-2	2

RefSeq proteins (4): NP_001276103, NP_001276104, NP_001276105, NP_072047* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007258	Vps52	Family
IPR048319	Vps52_CC	Domain
IPR048361	Vps52_C	Domain

Pfam: PF04129, PF20655

UniProt features (8 total): coiled-coil region 2, modified residue 2, initiator methionine 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N1B4-F1	86.10	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 355

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6811440	Retrograde transport at the Trans-Golgi-Network

MSigDB gene sets: 191 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, GCM_MAP4K4, FREAC2_01, GOBP_LYSOSOMAL_TRANSPORT, GCM_GSPT1, GCANCTGNY_MYOD_Q6, MORF_HDAC1, GOBP_PROTEIN_TARGETING, GOBP_VACUOLAR_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_DIGESTIVE_SYSTEM_DEVELOPMENT, GOBP_ECTODERM_DEVELOPMENT, MORF_SKP1A

GO Biological Process (9): protein targeting (GO:0006605), Golgi to vacuole transport (GO:0006896), lysosomal transport (GO:0007041), ectodermal cell differentiation (GO:0010668), protein transport (GO:0015031), endocytic recycling (GO:0032456), retrograde transport, endosome to Golgi (GO:0042147), embryonic ectodermal digestive tract development (GO:0048611), vesicle-mediated cholesterol transport (GO:0090119)

GO Molecular Function (2): syntaxin binding (GO:0019905), protein binding (GO:0005515)

GO Cellular Component (12): GARP complex (GO:0000938), Golgi apparatus (GO:0005794), cytosol (GO:0005829), endosome membrane (GO:0010008), membrane (GO:0016020), trans-Golgi network membrane (GO:0032588), perinuclear region of cytoplasm (GO:0048471), recycling endosome (GO:0055037), presynapse (GO:0098793), postsynapse (GO:0098794), EARP complex (GO:1990745), endosome (GO:0005768)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Intra-Golgi and retrograde Golgi-to-ER traffic	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	3
establishment of protein localization	2
vacuolar transport	2
intercellular transport	2
endosomal transport	2
cytosolic transport	2
cytoplasmic vesicle	2
endomembrane system	2
endosome	2
synapse	2
post-Golgi vesicle-mediated transport	1
ectoderm development	1
cell differentiation	1
transport	1
intracellular protein localization	1
vesicle-mediated transport to the plasma membrane	1
ectodermal digestive tract development	1
embryonic digestive tract development	1
vesicle-mediated transport	1
intracellular cholesterol transport	1
SNARE binding	1
binding	1
Golgi apparatus	1
vesicle tethering complex	1
intracellular membrane-bounded organelle	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
trans-Golgi network	1
organelle membrane	1
protein-containing complex	1
recycling endosome	1

Protein interactions and networks

STRING

1328 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VPS52	VPS53	Q5VIR6	998
VPS52	VPS54	Q9P1Q0	997
VPS52	VPS51	Q9UID3	997
VPS52	VPS50	Q96JG6	887
VPS52	SOAT2	O75908	856
VPS52	RPS18	P25232	846
VPS52	COG3	Q96JB2	832
VPS52	SOAT1	P35610	792
VPS52	STX16	O14662	771
VPS52	COG6	Q9Y2V7	758
VPS52	EXOC1	Q9NV70	715
VPS52	VTI1A	Q96AJ9	708
VPS52	RAB6A	P20340	694
VPS52	VAMP4	O75379	671
VPS52	EXOC7	Q9UPT5	671

IntAct

497 interactions, top by confidence:

A	B	Type	Score
VPS50	VPS53	psi-mi:“MI:0914”(association)	0.840
VPS52	VPS50	psi-mi:“MI:0915”(physical association)	0.830
TXLNA	VPS52	psi-mi:“MI:0915”(physical association)	0.780
VPS52	RNF41	psi-mi:“MI:0915”(physical association)	0.780
VPS52	TBC1D22B	psi-mi:“MI:0915”(physical association)	0.780
VPS52	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
RNF41	VPS52	psi-mi:“MI:0915”(physical association)	0.780
TBC1D22B	VPS52	psi-mi:“MI:0915”(physical association)	0.780
PSMC5	PSMD11	psi-mi:“MI:0914”(association)	0.730
VPS52	USP2	psi-mi:“MI:0915”(physical association)	0.720
VPS52	DDX6	psi-mi:“MI:0915”(physical association)	0.720
MFAP1	VPS52	psi-mi:“MI:0915”(physical association)	0.720
VPS52	WTAP	psi-mi:“MI:0915”(physical association)	0.720
TSTD2	VPS52	psi-mi:“MI:0915”(physical association)	0.720
VPS52	PPP1R18	psi-mi:“MI:0915”(physical association)	0.720
EPM2AIP1	VPS52	psi-mi:“MI:0915”(physical association)	0.720
GOLGA1	VPS52	psi-mi:“MI:0915”(physical association)	0.720
TSSK3	VPS52	psi-mi:“MI:0915”(physical association)	0.720
TXN2	VPS52	psi-mi:“MI:0915”(physical association)	0.720
AIRIM	VPS52	psi-mi:“MI:0915”(physical association)	0.720
TRAF6	VPS52	psi-mi:“MI:0915”(physical association)	0.720
ATP6V1D	VPS52	psi-mi:“MI:0915”(physical association)	0.720
USP2	VPS52	psi-mi:“MI:0915”(physical association)	0.720
DDX6	VPS52	psi-mi:“MI:0915”(physical association)	0.720
VPS52	MFAP1	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (283): VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), VPS52 (Two-hybrid), TEAD4 (Two-hybrid), TPM3 (Two-hybrid), TRAF6 (Two-hybrid), LMO4 (Two-hybrid), STX11 (Two-hybrid)

ESM2 similar proteins: A1A4I4, A2SXS5, A6QQ47, B2DCZ9, O00255, O08908, O55166, O75146, O88559, P70268, Q0P5I0, Q0VCR8, Q155U0, Q16512, Q29RB1, Q2KJ58, Q3MHG0, Q3MII6, Q3SZI7, Q3UVL4, Q4V9Y0, Q505L3, Q5R7R6, Q5TJF0, Q5ZJ25, Q63433, Q63788, Q68FF6, Q68FP9, Q69Z89, Q6PB44, Q6ZT62, Q865S3, Q8BI71, Q8BZQ7, Q8C190, Q8C754, Q8N1B4, Q8R1U1, Q8R3I3

Diamond homologs: G5EFV8, O55166, Q5TJF0, Q8C754, Q8N1B4, Q94KD3, Q9FVV6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RNF41	“down-regulates quantity by destabilization”	VPS52	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 81 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Retrograde transport at the Trans-Golgi-Network	5	22.0×	1e-03
AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)	5	19.4×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
endocytic recycling	7	27.1×	3e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	0
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3326 predictions. Top by Δscore:

Variant	Effect	Δscore
6:33251855:CATA:C	donor_loss	1.0000
6:33251856:ATACC:A	donor_loss	1.0000
6:33251857:TACC:T	donor_loss	1.0000
6:33251858:A:C	donor_loss	1.0000
6:33251859:C:G	donor_loss	1.0000
6:33251968:ATTCC:A	acceptor_loss	1.0000
6:33251969:TTCC:T	acceptor_loss	1.0000
6:33251970:TCCT:T	acceptor_loss	1.0000
6:33251971:CCTGG:C	acceptor_loss	1.0000
6:33251973:T:G	acceptor_loss	1.0000
6:33263545:CGCTC:C	acceptor_gain	1.0000
6:33263547:CTC:C	acceptor_gain	1.0000
6:33263548:TC:T	acceptor_gain	1.0000
6:33263548:TCCT:T	acceptor_loss	1.0000
6:33263549:CC:C	acceptor_gain	1.0000
6:33263550:C:CC	acceptor_gain	1.0000
6:33263550:CT:C	acceptor_loss	1.0000
6:33263786:G:C	donor_gain	1.0000
6:33263828:T:TA	donor_gain	1.0000
6:33263881:T:C	acceptor_loss	1.0000
6:33264398:C:A	donor_gain	1.0000
6:33264801:C:A	donor_gain	1.0000
6:33266616:C:CT	acceptor_gain	1.0000
6:33267646:AAGG:A	donor_gain	1.0000
6:33267736:CATA:C	acceptor_gain	1.0000
6:33267740:C:CC	acceptor_gain	1.0000
6:33267859:CCTTA:C	donor_loss	1.0000
6:33267860:CTTAC:C	donor_loss	1.0000
6:33267862:TAC:T	donor_loss	1.0000
6:33267863:ACCTG:A	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000532472 (6:33257018 G>T), RS1000730962 (6:33264492 C>G,T), RS1000779401 (6:33250292 A>G), RS1000807229 (6:33269923 A>C), RS1001184413 (6:33264132 C>G), RS1001799027 (6:33255919 G>C,T), RS1001899236 (6:33263939 G>A), RS1002011 (6:33250460 G>A), RS1002076048 (6:33270403 T>G), RS1002583131 (6:33259973 A>C,T), RS1002628716 (6:33260961 T>C), RS1002696843 (6:33273466 GTCT>G,GTCTTCT), RS1002727320 (6:33267014 G>A), RS1002733868 (6:33267625 G>A), RS1002807468 (6:33273686 C>T)

Disease associations

OMIM: gene MIM:603443 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder with or without congenital anomalies	Moderate	Autosomal recessive

Mondo (1): complex neurodevelopmental disorder with or without congenital anomalies (MONDO:0100465)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004521_287	Autism spectrum disorder or schizophrenia	5.000000e-08
GCST005951_153	Body mass index	5.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	6
bisphenol A	decreases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
(+)-JQ1 compound	decreases expression	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Cisplatin	affects response to substance	1
Dexamethasone	affects cotreatment, increases expression	1
Fluorouracil	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Thiram	decreases expression	1
Tretinoin	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TX68	HAP1 VPS52 (-) 1	Cancer cell line	Male
CVCL_TX69	HAP1 VPS52 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.